SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-085347
Filing Date
2024-07-22
Accepted
2024-07-22 17:25:09
Documents
12
Period of Report
2024-07-21
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K meip-20240722.htm   iXBRL 8-K 48329
2 EX-99.1 meip-ex99_1.htm EX-99.1 18198
  Complete submission text file 0000950170-24-085347.txt   178811

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT meip-20240722.xsd EX-101.SCH 23892
15 EXTRACTED XBRL INSTANCE DOCUMENT meip-20240722_htm.xml XML 4524
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

IRS No.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41827 | Film No.: 241132353
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)